Chitosan hydrogel vaccine generates protective CD8 T cell memory against mouse melanoma

Immunology and Cell Biology

Volumn 93, Issue 7, 2015, Pages 634-640

  Highton, Andrew J ^a   Kojarunchitt, Thunjiradasiree ^a   Girardin, Adam ^a   Hook, Sarah ^a   Kemp, Roslyn A ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CHITOSAN; DENDRITIC CELL VACCINE; DOPACHROME TAUTOMERASE; OVALBUMIN; QUIL A; T LYMPHOCYTE RECEPTOR; DELAYED RELEASE FORMULATION; HYDROGEL; IMMUNOLOGICAL ADJUVANT; OVA-8; PEPTIDE FRAGMENT; QUILLAJA SAPONIN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNIZATION; CD8+ T LYMPHOCYTE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY ASSAY; DENDRITIC CELL; DRUG CYTOTOXICITY; HYDROGEL; IN VIVO STUDY; LIMIT OF DETECTION; LYMPHOCYTE SUBPOPULATION; MELANOMA; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; SUSTAINED DRUG RELEASE; SUSTAINED RELEASE PREPARATION; TARGET CELL; TUMOR IMMUNITY; TUMOR VOLUME; ANIMAL; C57BL MOUSE; CYTOTOXICITY; DELAYED RELEASE FORMULATION; GERMFREE ANIMAL; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; MELANOMA, EXPERIMENTAL; TRANSGENIC MOUSE;

MUS;

ADJUVANTS, IMMUNOLOGIC; ADOPTIVE TRANSFER; ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CHITOSAN; CYTOTOXICITY, IMMUNOLOGIC; DELAYED-ACTION PREPARATIONS; DENDRITIC CELLS; HYDROGELS; IMMUNOLOGIC MEMORY; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OVALBUMIN; PEPTIDE FRAGMENTS; QUILLAJA SAPONINS; SPECIFIC PATHOGEN-FREE ORGANISMS;

EID: 84938959293     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2015.14     Document Type: Article

References (46)

1. Veiga-Fernandes H, Walter U, Bourgeois C, McLean A, Rocha B. Response of naïve and memory CD8+ T cells to antigen stimulation in vivo. Nat Immunol 2000; 1: 47-53.
2. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, et al. Bone marrowderived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995; 1: 1297-1302.
3. Porgador A, Snyder D, Gilboa E. Induction of antitumor immunity using bone marrowgenerated dendritic cells. J Immunol 1996; 156: 2918-2926.
4. Ludewig B, Ehl S, Karrer U, Odermatt B, Hengartner H, Zinkernagel RM. Dendritic cells efficiently induce protective antiviral immunity. J Virol 1998; 72: 3812-3818.
5. Ghasemi M, Erturk M, Buruk K, Sonmez M. Induction of potent protection against acute and latent herpes simplex virus infection in mice vaccinated with dendritic cells. Cytotherapy 2013; 15: 352-361.
6. Schadendorf D, Ugurel S, Schuler-Thurner B, Nestle FO, Enk A, Bröcker E-B, et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 2006; 17: 563-570.
7. Chi M, Dudek AZ. Vaccine therapy for metastatic melanoma: systematic review and meta-analysis of clinical trials. Melanoma Res 2011; 21: 165-174.
8. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 2003; 421: 852-856.
9. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005; 5: 296-306.
10. Lofthouse S. Immunological aspects of controlled antigen delivery. Adv Drug Deliv Rev 2002; 54: 863-870.
11. Bijker MS, van den Eeden SJF, Franken KL, Melief CJM, van der Burg SH, Offringa R. Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation. Eur J Immunol 2008; 38: 1033-1042.
12. Cockburn IA, Chen YYC, Overstreet MGM, Lees JR, van Rooijen N, Farber DL, et al. Prolonged antigen presentation is required for optimal CD8+ T cell responses against malaria liver stage parasites. PLoS Pathog 2010; 6: 1-13.
13. Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, Altman JD, et al. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med 1998; 188: 2205-2213.
14. Gallimore A, Glithero A, Godkin A, Tissot AC, Plckthun A, Elliott T, et al. Induction and exhaustion of Lymphocytic Choriomeningitis virus-specific cytotoxic T lymphocytes visualized using class I-peptide complexes. J Exp Med 1998; 187: 1383-1393.
15. Wherry EJ. T cell exhaustion. Nat Immunol 2011; 131: 492-499.
16. Zinkernagel RM, Ehl S, Aichele P, Oehen S, Kndig T, Hengartner H. Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunol Rev 1997; 156: 199-209.
17. Gordon S, Saupe A, McBurney W, Rades T, Hook S. Comparison of chitosan nanoparticles and chitosan hydrogels for vaccine delivery. J Pharm Pharmacol 2008; 60: 1591-1600.
18. Han I-K, Kim YB, Kang H-S, Sul D, Jung W-W, Cho HJ, et al. Thermosensitive and mucoadhesive delivery systems of mucosal vaccines. Methods 2006; 38: 106-111.
19. Chenite A, Chaput C, Wang D, Combes C, Buschmann MD, Hoemann CD, et al. Novel injectable neutral solutions of chitosan form biodegradable gels in situ. Biomaterials 2000; 21: 2155-2161.
20. Gordon S, Young K, Wilson R, Rizwan S, Kemp R, Rades T, et al. Chitosan hydrogels containing liposomes and cubosomes as particulate sustained release vaccine delivery systems. J Liposome Res 2012; 22: 193-204.
21. Porgador A, Gilboa E. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med 1995; 182: 255-260.
22. Gordon S, Teichmann E, Young K, Finnie K, Rades T, Hook S. In vitro and in vivo investigation of thermosensitive chitosan hydrogels containing silica nanoparticles for vaccine delivery. Eur J Pharm Sci 2010; 41: 360-368.
23. Lau L, Jamieson B, Somasundaram T, Ahmed R. Cytotoxic T-cell memory without antigen. Nature 1994; 369: 648-652.
24. Murali-Krishna K, Altman JD, Suresh M, Sourdive DJ, Zajac AJ, Miller JD, et al. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 1998; 8: 177-187.
25. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR. T cell receptor antagonist peptides induce positive selection. Cell 1994; 76: 17-27.
26. Brown DM, Fisher TL, Wei C, Frelinger JG, Lord EM. Tumours can act as adjuvants for humoral immunity. Immunology 2001; 102: 486-497.
27. Schluns KS, Williams K, Ma A, Zheng XX, Lefranois L. Cutting edge: requirement for IL-15 in the generation of primary and memory antigen-specific CD8 T cells. J Immunol 2002; 168: 4827-4831.
28. Kennedy MK, Glaccum M, Brown SN, Butz EA, Viney JL, Embers M, et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15- deficient mice. J Exp Med 2000; 191: 771-780.
29. Lodolce JP, Boone DL, Chai S, Swain RE, Dassopoulos T, Trettin S, et al. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 1998; 9: 669-676.
30. Becker TC. Interleukin 15 Is required for proliferative renewal of virus-specific memory CD8 T cells. J Exp Med 2002; 195: 1541-1548.
31. Burkett PR, Koka R, Chien M, Chai S, Chan F, Ma A, et al. IL-15R alpha expression on CD8+ T cells is dispensable for T cell memory. Proc Natl Acad Sci USA 2003; 100: 4724-4729.
32. Pihlgren M, Dubois PM, Tomkowiak M, Sjögren T, Marvel J, Pihlgren BM. Resting memory CD8+ T cells are hyperreactive to antigenic challenge in vitro. J Exp Med 1996; 184: 2141-2151.
33. Cho BK, Wang C, Sugawa S, Eisen HN, Chen J. Functional differences between memory and naive CD8 T cells. Proc Natl Acad Sci USA 1999; 96: 2976-2981.
34. Buentke E, Mathiot A, Tolaini M, Di Santo J, Zamoyska R, Seddon B. Do CD8 effector cells need IL-7R expression to become resting memory cells? Blood 2006; 108: 1949-1956.
35. Met Ö, Buus S, Claesson MH. Peptide-loaded dendritic cells prime and activate MHCclass I-restricted T cells more efficiently than protein-loaded cross-presenting DC. Cell Immunol 2003; 222: 126-133.
36. Gooden MJM, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 2011; 105: 93-103.
37. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369: 122-133.
38. Whitmire JK, Eam B, Whitton JL. Tentative T cells: memory cells are quick to respond, but slow to divide. PLoS Pathog 2008; 4: e1000041.
39. Mandraju R, Murray S, Forman J, Pasare C. Differential ability of surface and endosomal TLRs to induce CD8 T cell responses in vivo. J Immunol 2014; 192: 4303-4315.
40. Perez-Diez A, Joncker NT, Choi K, Chan WFN, Anderson CC, Lantz O, et al. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 2007; 109: 5346-5354.
41. Strebel PM, Sutter RW, Cochi SL, Biellik RJ, Brink EW, Kew OM, et al. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis 1992; 14: 568-579.
42. Storni T, Kndig TM, Senti G, Johansen P. Immunity in response to particulate antigendelivery systems. Adv Drug Deliv Rev 2005; 57: 333-355.
43. Myschik J, McBurney WT, Hennessy T, Phipps-Green A, Rades T, Hook S. Immunostimulatory biodegradable implants containing the adjuvant Quil-A-Part II: in vivo evaluation. J Drug Target 2008; 16: 224-232.
44. Tang Y, Wang X, Li Y, Lei M, Du Y, Kennedy JF, et al. Production and characterisation of novel injectable chitosan/methylcellulose/salt blend hydrogels with potential application as tissue engineering scaffolds. Carbohydr Polym 2010; 82: 833-841.
45. Garrigan K, Moroni-Rawson P, McMurray C, Hermans I, Abernethy N, Watson J, et al. Functional comparison of spleen dendritic cells and dendritic cells cultured in vitro from bone marrow precursors. Blood 1996; 88: 3508-3512.
46. Hermans IF, Daish A, Moroni-Rawson P, Ronchese F. Tumor-peptide-pulsed dendritic cells isolated from spleen or cultured in vitro from bone marrow precursors can provide protection against tumor challenge. Cancer Immunol Immunother 1997; 44: 341-347.